Psoriasis: risk-benefit profile similar for tofacitinib vs other systemic therapies

  • Strober BE & al.
  • Br J Dermatol
  • 6 Sep 2018

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Pooled analysis of 6 clinical trials indicates that tofacitinib treatment is well tolerated and has a similar benefit-risk profile as other systemic treatments in patients with moderate to severe chronic plaque psoriasis.

Why this matters

  • Tofacitinib appears to be a safe and effective alternative for patients with moderate to severe psoriasis, particularly those who require treatment switching.

Key results

  • Greater proportions of patients receiving tofacitinib 5 or 10 mg twice daily vs placebo achieved Physician’s Global Assessment (PGA) "clear" or "almost clear" (44.0%, 59.1%, and 10.0%, respectively; P<.0001 and improvement in psoriasis area severity index respectively p at week>
  • Adverse events (AEs) were reported in 54.0% of patients who received tofacitinib 5 mg twice daily, 58.9% of patients who received tofacitinib 10 mg twice daily, and 50.4% of patients who received placebo.
    • 2.6%, 3.1%, and 4.9%, respectively, discontinued because of AEs.
    • In tofacitinib-treated patients, the most frequently observed serious infections were pneumonia (0.4%), herpes zoster (0.2%), and appendicitis (0.2%).

Study design

  • Data from 1 phase 2 trial, 4 phase 3 trials, and 1 long-term extension study were pooled to analyze the efficacy and safety of tofacitinib.
  • Funding: Pfizer Inc.

Limitations

  • Clinical trial population may not match real-world settings.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit